<DOC>
	<DOCNO>NCT00274911</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , lomustine , cisplatin , vincristine , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy follow combination chemotherapy surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give radiation therapy follow combination chemotherapy work treat young patient supratentorial primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Radiation Therapy Followed By Combination Chemotherapy Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity hyperfractionated accelerated radiotherapy ( HART ) pediatric patient nonpineal supratentorial primitive neuroectodermal tumor . Secondary - Determine overall relapse-free survival patient treat HART follow adjuvant combination chemotherapy comprise lomustine , cisplatin , vincristine . - Determine toxicity regimen patient . OUTLINE : This multicenter study . - Radiotherapy : Patients undergo hyperfractionated accelerated radiotherapy ( HART ) twice day , 5 day week , 5 week . - Adjuvant combination chemotherapy : Six week last radiotherapy dose , patient receive oral lomustine cisplatin IV 6 hour day 1 vincristine IV day 1 , 8 , 15 . Treatment repeat every 6 week 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven nonpineal supratentorial primitive neuroectodermal tumor No supratentorial atypical teratoid/rhabdoid tumor medulloepitheliomas Localized metastatic disease Metastatic disease define unequivocal evidence supratentorial metastasis and/or spinal metastasis preoperative postoperative MRI scan OR tumor cell see cytospin analysis lumbar cerebrospinal fluid ( stage M1 ) perform 15 day 21 day surgery Has undergone surgical resection within past 46 week PATIENT CHARACTERISTICS : Able cooperate twice daily fraction radiotherapy Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Neurologically stable ( improve ) week start radiotherapy Lansky performance status 30100 % ( patient 1 16 year age ) OR Karnofsky performance status 30100 % ( patient 16 year age ) Must able comply chemotherapy protocol ( e.g. , hearing loss , renal impairment ) No presence active uncontrolled infection No previous malignant disease Not pregnant nursing No syndrome recognize potential increased sensitivity radiotherapy and/or chromosomal fragility PRIOR CONCURRENT THERAPY : No previous chemotherapy radiotherapy The patient receive steroid , possible , start radiotherapy stable reduce dose steroid week start radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
</DOC>